ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
Dow Jones
40,589.34
1.64%
US Dollar vs MXN
18.4592
0.00%
Brent Oil
79.745
0.00%
Bitcoin
68,160.63
0.36%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Albireo Pharma Inc (ALBO)

  7. Albireo Pharma Inc (ALBO) Noticias

ALBO

Albireo Pharma (ALBO)

Albireo Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALBO
FechaHoraFuenteTítuloSímboloCompañía
14/02/202407:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALBOAlbireo Pharma Inc
09/03/202305:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALBOAlbireo Pharma Inc
03/03/202305:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202315:53Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202315:49Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202315:32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202315:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202310:29Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202310:24Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ALBOAlbireo Pharma Inc
27/02/202315:06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202315:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202307:30GlobeNewswire Inc.FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeNASDAQ:ALBOAlbireo Pharma Inc
27/01/202316:29Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ALBOAlbireo Pharma Inc
23/01/202307:13Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ALBOAlbireo Pharma Inc
19/01/202315:12Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ALBOAlbireo Pharma Inc
10/01/202305:07Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ALBOAlbireo Pharma Inc
21/12/202215:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALBOAlbireo Pharma Inc
20/12/202215:30GlobeNewswire Inc.Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALBOAlbireo Pharma Inc
19/12/202207:30GlobeNewswire Inc.Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMANASDAQ:ALBOAlbireo Pharma Inc
08/12/202211:35TipRanksWedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
06/12/202207:30GlobeNewswire Inc.Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNASDAQ:ALBOAlbireo Pharma Inc
09/11/202207:30GlobeNewswire Inc.Albireo to Participate in Jefferies London Healthcare ConferenceNASDAQ:ALBOAlbireo Pharma Inc
09/11/202205:46TipRanksWedbush Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
09/11/202205:35TipRanksH.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202215:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202215:01GlobeNewswire Inc.Albireo Reports Q3 2022 Financial Results and Business UpdateNASDAQ:ALBOAlbireo Pharma Inc
07/11/202207:30GlobeNewswire Inc.Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNASDAQ:ALBOAlbireo Pharma Inc
03/11/202207:30GlobeNewswire Inc.Albireo Announces 2022 SPARK Grant WinnersNASDAQ:ALBOAlbireo Pharma Inc
02/11/202207:30GlobeNewswire Inc.Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNASDAQ:ALBOAlbireo Pharma Inc
01/11/202207:30GlobeNewswire Inc.Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022NASDAQ:ALBOAlbireo Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ALBO

Su Consulta Reciente

FX
USDMXN
US Dollar vs MXN
NYSE
VZ
Verizon Communications
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
NASDAQ
TSLA
Tesla
NYSE
CVX
Chevron
NASDAQ
AMZN
Amazon.com
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
PM
XAUUSD
Gold vs US Dollar
CCOM
US30
US 30
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
AXP
American Express
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados